(Reuters) – Danish biotechnology company Bavarian Nordic revised its annual guidance on Monday for a second time after signing supply contracts with several undisclosed countries for its Imvanex monkeypox vaccine. Bavarian Nordic said vaccine deliveries would start immediately and added that it was in discussions with more countries regarding vaccine supply. “We are pleased to assist more countries with supply of vaccines while we continue our dialogues with other governments to make vaccines available as fast as possible to mitigate the situation,” CEO Paul Chaplin said in a statement. Bavari…